ABSTRACT

RX-P873 is a novel agent under development by Rib-X Pharmaceuticals. RX-P873 possesses potent, rapid in vivo activity against multidrug-resistant (MDR) Klebsiella pneumoniae. RX-P873 was evaluated in the current murine thigh infection model.

BACKGROUND:

Rib-X Pharmaceuticals is currently under development by Rib-X Pharmaceuticals.

MATERIALS AND METHODS:

Antimicrobial agents were isolated from a strain of K. pneumoniae (KP457, MIC 0.06 μg/mL) was evaluated using the murine thigh infection model.

CONCLUSIONS:

While dose fractionation studies showed a trend toward enhanced activity relative to KP457, the final active in vivo action of RX-P873 is defined only by further investigations of the pharmacodynamic indices.

REFERENCE: